Tag: Inhaled

Posted on

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Fluticasone Furoate;   Drug: Vilanterol;   Drug: Fluticasone propionate;   Drug: Salmeterol;   Drug: Budesonide;   Drug: Formoterol Fumarate
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified May 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

Inhaled Statins: The Future of Asthma Treatment? – Monthly Prescribing Reference (registration)


News-Medical.net

Inhaled Statins: The Future of Asthma Treatment?
Monthly Prescribing Reference (registration)
In this study, scientists developed a new method to measure statin levels in mice after treatment with inhaled statins and improvement in asthma symptoms. When administered as a spray, the drug was found to be nontoxic and delivered primarily to the …
UC Davis researchers show feasibility of using statins to treat asthmaNews-Medical.net

all 4 news articles »

View full post on asthma – Google News

Posted on

High-Dose Inhaled Salbutamol Does Not Improve 10-km Cycling Time-Trial Performance.

Related Articles

High-Dose Inhaled Salbutamol Does Not Improve 10-km Cycling Time-Trial Performance.

Med Sci Sports Exerc. 2015 Apr 8;

Authors: Koch S, Ahn JR, Koehle MS

Abstract
BACKGROUND: ?2-agonists are on the World Anti-Doping Agency’s (WADA) list of prohibited substances; however, athletes are allowed to treat symptoms of exercise-induced bronchoconstriction with a maximal daily dose of 1600 ?g of salbutamol when taken up by inhalation.
PURPOSE: To investigate if 1600 ?g of salbutamol lead to an enhanced time-trial performance in trained, competitive male cyclists, with and without exercise-induced bronchoconstriction, based on inhaled dose per kilogram of body weight (kg/BW).
METHODS: In a randomized, crossover design, 20 trained male cyclists (8 with a positive eucapnic voluntary hyperpnea challenge (EVH+) and 12 with a negative EVH challenge (EVH-) performed two simulated 10-km time-trials on a cycle ergometer 30-min after the inhalation of either 1600 ?g of salbutamol or placebo. Lung function, assessed by forced expiratory volume in 1 second (FEV1), was measured immediately before and 15 min after inhalation. The main performance outcome was mean power output.
RESULTS: After the inhalation of salbutamol, FEV1 was significantly increased by 6.4% (4.9%) vs. 1.0% (4.4%) with placebo (p < 0.001). Despite this increase in FEV1, mean power output during the salbutamol time-trial was not increased, regardless of relative dose per kg/BW and asthma status. Mean heart rate (p = 0.01), respiratory rate (p = 0.01) and minute ventilation (p = 0.03) and perceived leg discomfort (p = 0.03) were significantly increased in the salbutamol condition.
CONCLUSIONS: The inhalation of 1600?g salbutamol improved FEV1 regardless of EVH-status, but did not improve 10-km time-trial performance in trained, competitive male cyclists, regardless of relative dose per kg/BW or EVH-status. Significant increases in heart rate and minute ventilation occurred secondary to stimulation of the adrenergic nervous system.

PMID: 25856682 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Effect of Common Comparators in Indirect Comparison Analysis of the Effectiveness of Different Inhaled Corticosteroids in the Treatment of Asthma.

Effect of Common Comparators in Indirect Comparison Analysis of the Effectiveness of Different Inhaled Corticosteroids in the Treatment of Asthma.

PLoS One. 2015;10(3):e0120836

Authors: Kunitomi T, Hashiguchi M, Mochizuki M

Abstract
PURPOSE: Indirect comparison (IC) and direct comparison (DC) of four inhaled corticosteroid (CS) treatments for asthma were conducted, and the factors that may influence the results of IC were investigated. Among those factors, we focused on the effect of common comparator selection in the treatment of asthma, where little control group bias or placebo effect is expected.
METHOD: IC and DC were conducted using the change from baseline in forced expiratory volume in 1 s (FEV1(L)) as an outcome parameter. Differences between inhaled CS were evaluated to compare the results of IC and DC. As a common comparator for IC, placebo (PLB) or mometasone (MOM) was selected. Whether the results of IC are affected by the selection of a common comparator and whether the results of IC and DC are consistent were examined.
RESULTS: 23 articles were identified by a literature search. Our results showed that ICs yielded results similar to DCs in the change from baseline of FEV1(L). No statistically significant difference was observed in inconsistency analysis between ICs and DCs. It was clinically and statistically confirmed that ICs with PLB and those with MOM did not differ in terms of the results of FEV1(L) analysis in this dataset.
CONCLUSION: This study demonstrated that ICs among inhaled CS can deliver results consistent with those of DCs when using the change from baseline in FEV1(L) as an outcome parameter in asthma patients. It was also shown that using an active comparator has similar results if there is no effect of control group bias. It should be emphasized that the investigation of control group bias is a key factor in conducting relevant ICs so that an appropriate common comparator can be selected.

PMID: 25793900 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

Is it safe to use inhaled corticosteroids in pregnancy?

Related Articles

Is it safe to use inhaled corticosteroids in pregnancy?

Can Fam Physician. 2014 Sep;60(9):809-12

Authors: Smy L, Chan AC, Bozzo P, Koren G

Abstract
QUESTION: A healthy woman with mild to moderate asthma came to my clinic today after learning that she was pregnant. She inquired about continuing her inhaled corticosteroid (ICS) medication and whether there would be any risks to her unborn child if she were to do so. What would you advise?
ANSWER: Given the published evidence, ICSs should be continued throughout pregnancy at low to moderate doses sufficient to control asthma symptoms and prevent exacerbations. However, caution must be taken with doses greater than 1000 µg/d (chlorofluorocarbon beclomethasone equivalent), although whether such doses cause adverse effects is currently still questionable. Patient education on proper ICS administration and adherence, including during the first trimester, must be ongoing. Well controlled asthma will reduce the need for higher ICS doses and possible exposure to systemic corticosteroids, and might decrease the risk of adverse pregnancy or perinatal outcomes.

PMID: 25217675 [PubMed – in process]

View full post on pubmed: asthma